Brief: Uniqure - Cash Position Of Approximately $660 Million As Of September 30, 2023 Expected To Fund Operations Into Q2 2027
Nov 7 (Reuters) - Uniqure NV UQ1.F :
* STRONG CASH POSITION OF APPROXIMATELY $660 MILLION AS OF
SEPTEMBER 30, 2023 EXPECTED TO FUND OPERATIONS INTO Q2 OF 2027
* ON TRACK TO PROVIDE CLINICAL UPDATE FROM U.S. AND EUROPEAN
PHASE
I/II TRIALS OF AMT-130 IN HUNTINGTON'S DISEASE LATER IN Q4 OF
2023
* EXPECT TO DELIVER $180 MILLION OF COST SAVINGS OVER NEXT
THREE
YEARS
* QTRLY LOSS PER SHARE $ 1.88
* Q3 EARNINGS PER SHARE VIEW $-0.85 -- LSEG IBES DATA
Source text for Eikon: ID:nGNX5f6J0h
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal